Gossamer Bio Q2 FY26 returns to profit at $16.9 million; revenue falls 19.6% to $9.24 million

Reuters2026/08/13 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gossamer Bio posted Q2 net income of USD 16.9 million, swinging from a net loss a year earlier.
Revenue fell 19.59% to USD 9.24 million, reflecting collaboration revenue tied to Chiesi.
R&D expenses dropped 36.48% to USD 26.41 million on lower clinical-trial costs for seralutinib.
Cash, cash equivalents and marketable securities totaled USD 57.03 million at June 30, with funding expected into Q1 2027.
Pre-NDA Type B minutes keep a seralutinib PAH NDA on track for September 2026; worldwide rights were reacquired from Chiesi.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608131601BIZWIRE_USPR_____20260813_BW025520) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gossamer Bio Q2 FY26 returns to profit at $16.9 million; revenue falls 19.6% to $9.24 million

You may also like

Crypto prices